ATAI
Price
$2.41
Change
-$0.07 (-2.82%)
Updated
Jun 6 closing price
Capitalization
522.65M
72 days until earnings call
GRCE
Price
$2.97
Change
+$0.01 (+0.34%)
Updated
Jun 6 closing price
Capitalization
40.74M
Interact to see
Advertisement

ATAI vs GRCE

Header iconATAI vs GRCE Comparison
Open Charts ATAI vs GRCEBanner chart's image
ATAI Life Sciences
Price$2.41
Change-$0.07 (-2.82%)
Volume$4.65M
Capitalization522.65M
Grace Therapeutics
Price$2.97
Change+$0.01 (+0.34%)
Volume$16.73K
Capitalization40.74M
ATAI vs GRCE Comparison Chart
Loading...
ATAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GRCE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATAI vs. GRCE commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATAI is a Buy and GRCE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (ATAI: $2.41 vs. GRCE: $2.97)
Brand notoriety: ATAI and GRCE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATAI: 226% vs. GRCE: 68%
Market capitalization -- ATAI: $522.65M vs. GRCE: $40.74M
ATAI [@Biotechnology] is valued at $522.65M. GRCE’s [@Biotechnology] market capitalization is $40.74M. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATAI’s FA Score shows that 1 FA rating(s) are green whileGRCE’s FA Score has 0 green FA rating(s).

  • ATAI’s FA Score: 1 green, 4 red.
  • GRCE’s FA Score: 0 green, 5 red.
According to our system of comparison, ATAI is a better buy in the long-term than GRCE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATAI’s TA Score shows that 7 TA indicator(s) are bullish while GRCE’s TA Score has 5 bullish TA indicator(s).

  • ATAI’s TA Score: 7 bullish, 3 bearish.
  • GRCE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ATAI is a better buy in the short-term than GRCE.

Price Growth

ATAI (@Biotechnology) experienced а +4.33% price change this week, while GRCE (@Biotechnology) price change was +7.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

ATAI is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATAI($523M) has a higher market cap than GRCE($40.7M). ATAI YTD gains are higher at: 81.203 vs. GRCE (-20.588). GRCE has higher annual earnings (EBITDA): -16.72M vs. ATAI (-124.33M). ATAI has more cash in the bank: 85.9M vs. GRCE (11.1M). ATAI has higher revenues than GRCE: ATAI (331K) vs GRCE (0).
ATAIGRCEATAI / GRCE
Capitalization523M40.7M1,285%
EBITDA-124.33M-16.72M744%
Gain YTD81.203-20.588-394%
P/E RatioN/AN/A-
Revenue331K0-
Total Cash85.9M11.1M774%
Total Debt23.8MN/A-
FUNDAMENTALS RATINGS
ATAI vs GRCE: Fundamental Ratings
ATAI
GRCE
OUTLOOK RATING
1..100
2513
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
53
Fair valued
PROFIT vs RISK RATING
1..100
9546
SMR RATING
1..100
9592
PRICE GROWTH RATING
1..100
3558
P/E GROWTH RATING
1..100
14100
SEASONALITY SCORE
1..100
8742

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GRCE's Valuation (53) in the Pharmaceuticals Other industry is in the same range as ATAI (67) in the Miscellaneous Commercial Services industry. This means that GRCE’s stock grew similarly to ATAI’s over the last 12 months.

GRCE's Profit vs Risk Rating (46) in the Pharmaceuticals Other industry is somewhat better than the same rating for ATAI (95) in the Miscellaneous Commercial Services industry. This means that GRCE’s stock grew somewhat faster than ATAI’s over the last 12 months.

GRCE's SMR Rating (92) in the Pharmaceuticals Other industry is in the same range as ATAI (95) in the Miscellaneous Commercial Services industry. This means that GRCE’s stock grew similarly to ATAI’s over the last 12 months.

ATAI's Price Growth Rating (35) in the Miscellaneous Commercial Services industry is in the same range as GRCE (58) in the Pharmaceuticals Other industry. This means that ATAI’s stock grew similarly to GRCE’s over the last 12 months.

ATAI's P/E Growth Rating (14) in the Miscellaneous Commercial Services industry is significantly better than the same rating for GRCE (100) in the Pharmaceuticals Other industry. This means that ATAI’s stock grew significantly faster than GRCE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATAIGRCE
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
73%
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
76%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
75%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 1 day ago
79%
Declines
ODDS (%)
N/A
Bearish Trend 10 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 3 days ago
80%
Aroon
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
62%
View a ticker or compare two or three
Interact to see
Advertisement
ATAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GRCE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MRFIX60.65N/A
N/A
MFS Research I
RYCOX57.69N/A
N/A
Rydex NASDAQ-100® C
AIMOX17.15N/A
N/A
AQR International Momentum Style I
HILFX31.48N/A
N/A
Hennessy Large Cap Financial Instl
AGFGX12.27N/A
N/A
American Century Focused Global Gr R5

ATAI and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATAI has been loosely correlated with MNMD. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ATAI jumps, then MNMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATAI
1D Price
Change %
ATAI100%
-2.82%
MNMD - ATAI
54%
Loosely correlated
+1.30%
ABCL - ATAI
47%
Loosely correlated
+2.95%
RXRX - ATAI
47%
Loosely correlated
+20.13%
CYBN - ATAI
46%
Loosely correlated
+0.91%
CRSP - ATAI
46%
Loosely correlated
+8.53%
More

GRCE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GRCE has been loosely correlated with IMVT. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if GRCE jumps, then IMVT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRCE
1D Price
Change %
GRCE100%
+0.34%
IMVT - GRCE
38%
Loosely correlated
+4.68%
SLNO - GRCE
38%
Loosely correlated
+0.39%
CYTK - GRCE
36%
Loosely correlated
+0.69%
SCNI - GRCE
31%
Poorly correlated
-21.54%
ATAI - GRCE
30%
Poorly correlated
-2.82%
More